The consent form says participation is voluntary. Yet in some global clinical trials sponsored by organizations based elsewhere and conducted in lower-resource countries, joining a study may be the only realistic way to see a physician, receive diagnostic testing, obtain medication, or remain in care. When ordinary care is unavailable, how voluntary is the choice to participate?
This is not always coercion in the narrow legal sense. Rather, it reflects constrained voluntariness created by structural deprivation. International research is not inherently exploitative. Well-designed studies can address neglected diseases, strengthen health systems, and build scientific capacity. The ethical problem begins when communities in lower-resource settings bear the risks and burdens of research while the knowledge, products, and decision-making power flow to institutions and companies elsewhere.
When consent becomes a bureaucratic ritual
A signature does not prove that someone understood the study or chose freely. U.S. federal research guidance describes informed consent as a process involving disclosure, understanding, and voluntariness. It also makes clear that a signed form alone is not enough. The same ethical standard should guide research everywhere.
Real physician voices, twice a week
Free, and one click to unsubscribe.
Consent documents developed by sponsoring institutions may be translated word-for-word without being adapted to local language, literacy, culture, or health-system realities. A document can be technically accurate and still be difficult to understand.
Randomization, placebo assignment, the future use of biological samples, and the distinction between research and individualized treatment are complex concepts, even for highly educated patients. They may be even harder to understand when the research team is also providing the only care available.
Potential participants should be able to explain, in their own words, the study’s purpose, its main risks, reasonable alternatives, the possibility of receiving a placebo or control intervention, and their right to withdraw without losing the care otherwise available to them. When they cannot, the answer is not another signature. It is more time, clearer language, oral explanation, and a genuine opportunity to ask questions.
The injustice of abandonment after a trial
Even an exceptional consent process cannot make an unjust trial fair. The 2024 Declaration of Helsinki states that post-trial provisions must be arranged in advance for participants who still need an intervention that has been found to be beneficial and reasonably safe. Those arrangements must be explained during the consent process, and exceptions require approval from a research ethics committee.
The gap between that standard and practice is substantial. A peer-reviewed study of 193 clinical trial protocols submitted to the University of the Philippines Manila from 2012 through 2017 found that 100, or 51.8 percent, mentioned some form of post-trial access. Only 57 included provisions that even partially matched recognized ethical guidance. The most common provision, appearing in 40 protocols, was sharing information with participants. None clearly provided continued access to the intervention, although 10 contemplated a later sponsor assessment and seven mentioned a possible open-label extension.
Getting results is not the same as getting treatment, nor is regulatory approval the same as access. A JAMA Internal Medicine study published online in November 2025 examined 172 FDA-approved medicines from 2015 through 2018 that were tested across 89 countries. Of the 144 medicines tested outside the United States, only 34, or 24 percent, had received marketing authorization in every country where they were tested within five years of FDA approval. The proportion was 32 percent in high-income countries and 13 percent in lower-middle-income countries.
Marketing authorization does not guarantee that a medicine will be affordable, consistently available, or supported by a clinician who can prescribe and monitor it. This is how a community can help establish a product’s safety and effectiveness and still be unable to obtain it. During the trial, participants are treated as essential sources of data. Afterward, they may become no one’s responsibility.
A path toward structural justice
Justice requires more than aspirational language. Every international trial should have a funded, reviewable post-trial access plan before enrollment begins. The plan should specify who will provide a beneficial intervention, how it will be financed, which participants will qualify, how long access will continue, and who will provide ongoing monitoring and follow-up care.
Ethics committees should reject vague promises to work with local systems when those systems lack the resources to deliver the intervention. Regulators can reinforce this duty. When reviewing products supported by multinational trials, sponsors should be required to report whether promised post-trial arrangements were implemented. Public trial registries should also record those commitments and their outcomes. That transparency would make it harder for access plans to disappear once recruitment ends.
Consent needs stronger safeguards when illness, poverty, or unequal professional authority narrows a person’s choices. In those settings, locally fluent staff, shorter materials written for the community, oral explanations, teach-back questions, independent advocates, and community review should be routine when the risk of misunderstanding or undue influence is high. The ethical test is whether the participant understood and could realistically say no.
Local researchers and communities also need real authority before approaching the first participant. They should help choose the research question, design the protocol, govern data and samples, determine authorship, and plan how successful interventions will reach participants. A site that only recruits participants and follows instructions is not an equal partner.
Sponsors sometimes argue that stronger post-trial obligations would increase costs or shift research elsewhere. That is a reason to strengthen international standards, not weaken ethical principles. Harmonized requirements can help prevent an ethical race to the bottom. Ethical protections cannot become optional simply because they are costly to uphold.
A signed consent form cannot compensate for the absence of meaningful choices. Publishing results cannot substitute for continuing care. When communities accept the risks of research, they should also share in the knowledge, authority, and health benefits it creates.
This essay is cited in the KevinMD record on medical ethics.
Timothy Lesaca is a psychiatrist in private practice at New Directions Mental Health in Pittsburgh, Pennsylvania, with more than forty years of experience treating children, adolescents, and adults across outpatient, inpatient, and community mental health settings. He has published in peer-reviewed and professional venues including the Patient Experience Journal, Psychiatric Times, the Allegheny County Medical Society Bulletin, and other clinical journals, with work addressing topics such as open-access scheduling, Landau-Kleffner syndrome, physician suicide, and the dynamics of contemporary medical practice. His recent writing examines issues of identity, ethical complexity, and patient–clinician relationships in modern health care. Additional information about his clinical practice and professional work is available on his website, timothylesacamd.com. His professional profile also appears on his ResearchGate profile, where further publications and details may be found.
